Granted Patent
Utility
US 6,599,891
· Confirmation No. 9013
TREATMENT OF MACULAR EDEMA
Inventors
Attorneys & Agents of Record
Classification
USPC
601/15
A61K31/409
A61P27/02
A61K41/0071
Prosecution
- Examiner
- HENLEY III, RAYMOND J
- Art Unit
- 1614
- Customer No.
- 25225
- Docket No.
- 273012013100
- Confirmation No.
- 9013
Publication
- Pub. No.
- US20030099596A1
- Pub. Date
- 2003-05-29
Patent Term Adjustment
-88days
Parent
Claims priority from a provisional application
→
App. 60/306,731
Filed 2001-07-20
· Provisional Application Expired
Parent
Claims priority from a provisional application
→
App. 60/329,009
Filed 2001-10-12
· Provisional Application Expired
Child
is a Continuation of
→
App. 10/622,310
· US 7,015,240
Filed 2003-07-17
· Patented Case
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
COMMONWEALTH LABORATORIES, LLC,
DOW PHARMACEUTICAL SCIENCES, INC.,
ECR PHARMACEUTICALS CO., INC.,
LABORATOIRE CHAUVIN S.A.S.,
MEDICIS PHARMACEUTICAL CORPORATION,
ONPHARMA INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, LTD.,
SALIX PHARMACEUTICALS, INC.,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
SYNERGETICS USA, INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT CANADA LP,
VALEANT PHARMACEUTICALS INTERNATIONAL,
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC,
WIRRA IP PTY LIMITED,
VALEANT PHARMA POLAND SP. Z O.O.,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMACEUTICALS IRELAND LIMITED
RELEASE OF SECURITY INTEREST
Recorded 2025-11-20
BAUSCH HEALTH IRELAND LIMITED,
BAUSCH HEALTH COMPANIES INC.,
BAUSCH HEALTH, CANADA INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA,
VALEANT SP. Z.O.O.
RELEASE OF SECURITY INTEREST
Recorded 2025-11-20
SOLTA MEDICAL, INC.,
PRECISION DERMATOLOGY, INC.,
BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED),
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD,
SANTARUS, INC.,
MEDICIS PHARMACEUTICAL CORPORATION,
HUMAX PHARMACEUTICAL S.A.,
SOLTA MEDICAL IRELAND LIMITED,
BAUSCH & LOMB MEXICO, S.A. DE C.V.,
BAUSCH+LOMB OPS B.V.,
BAUSCH HEALTH AMERICAS, INC.,
BAUSCH HEALTH COMPANIES INC.,
BAUSCH HEALTH HOLDCO LIMITED,
BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC),
BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA),
BAUSCH HEALTH US, LLC,
BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.,
ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.),
ORAPHARMA, INC.,
PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.),
SOLTA MEDICAL DUTCH HOLDINGS B.V.,
V-BAC HOLDING CORP.,
VRX HOLDCO LLC,
1261229 B.C. LTD.,
1530065 B.C. LTD.
RELEASE OF SECURITY INTEREST
Recorded 2025-04-08
from
BAUSCH & LOMB IRELAND LIMITED,
BAUSCH HEALTH COMPANIES INC.,
DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH,
TECHNOLAS PERFECT VISION GMBH
SECURITY INTEREST
Recorded 2021-10-05
from
BAUSCH HEALTH COMPANIES INC.,
BAUSCH HEALTH IRELAND LIMITED,
BAUSCH HEALTH, CANADA INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA,
VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.,
VALEANT SP. Z O. O.
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded 2019-07-03
from
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
COMMONWEALTH LABORATORIES, LLC,
DOW PHARMACEUTICAL SCIENCES, INC.,
ECR PHARMACEUTICALS CO., INC.,
LABORATOIRE CHAUVIN S.A.S.,
MEDICIS PHARMACEUTICAL CORPORATION,
ONPHARMA INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD.,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
SYNERGETICS USA, INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT CANADA LP,
VALEANT PHARMA POLAND SP. Z O.O.,
VALEANT PHARMACEUTICALS INTERNATIONAL,
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS IRELAND LIMITED,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC,
WIRRA IP PTY LIMITED
SECURITY INTEREST
Recorded 2018-02-26
from
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSCH & LOMB PHARMA HOLDINGS CORP.,
COMMONWEALTH LABORATORIES, LLC,
DOW PHARMACEUTICAL SCIENCES, INC.,
ECR PHARMACEUTICALS CO., INC.,
LABORATOIRE CHAUVIN S.A.S.,
MEDICIS PHARMACEUTICAL CORPORATION,
ONPHARMA INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD.,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
SYNERGETICS USA, INC.,
TECHNOLAS PERFECT VISION GMBH,
VALEANT CANADA LP,
VALEANT PHARMA POLAND SP. Z O.O.,
VALEANT PHARMACEUTICALS INTERNATIONAL,
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS IRELAND LIMITED,
VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC,
WIRRA IP PTY LIMITED
SECURITY INTEREST
Recorded 2018-02-26
SECURITY INTEREST
Recorded 2017-07-19
from
ATON PHARMA, INC.,
BAUSCH & LOMB INCORPORATED,
BAUSH & LOMB PHARMA HOLDINGS CORP.,
DENDREON PHARMACEUTICALS, INC.,
DOW PHARMACEUTICAL SCIENCES, INC.,
MEDICIS PHARMACEUTICAL CORPORATION,
OBAGI MEDICAL PRODUCTS, INC.,
OMP, INC.,
ORAPHARMA, INC.,
PRECISION DERMATOLOGY, INC.,
SALIX PHARMACEUTICALS, INC.,
SALIX PHARMACEUTICALS, LTD,
SANTARUS, INC.,
SOLTA MEDICAL, INC.,
VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED,
VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA),
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
VALEANT PHARMACEUTICALS IRELAND,
VALEANT PHARMACEUTICALS NORTH AMERICA LLC
SECURITY INTEREST
Recorded 2016-07-18
ADDRESS CHANGE
Recorded 2014-05-15
PATENT ASSIGNMENT AGREEMENT
Recorded 2013-12-09
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded 2002-10-28
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this application's details
Quick Facts
- Patent No.
- US 6,599,891
- App. No.
- 10/199,662
- Filed
- 2002-07-19
- Granted
- 2003-07-29
- Pub. No.
- US20030099596A1
- Examiner
- HENLEY III, RAYMOND J
- Art Unit
- 1614
- PTA
- -88 days
External Links